Tarextumab: Completed Phase Ib/II enrollment

OncoMed completed enrollment of 145 patients with extensive-stage SCLC in the Phase II portion of the double-blind, placebo-controlled,

Read the full 187 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE